Longeveron (LGVN) Interest Coverage Ratio Growth (1y) (2021 - 2026)
Longeveron (LGVN) Interest Coverage Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -25.59% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,170.12% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 751.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.48% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.46% |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.67% |
| Mar 31, 2026 | -57.40% |
| Dec 31, 2025 | -42.67% |
| Sep 30, 2025 | 76.01% |
| Jun 30, 2025 | 94.87% |
| Mar 31, 2025 | 78.42% |
| Dec 31, 2024 | 97.47% |
| Sep 30, 2024 | 9.92% |
| Jun 30, 2024 | -210.28% |
| Mar 31, 2024 | -14,612.45% |
| Dec 31, 2023 | -140.18% |
| Sep 30, 2023 | 0.50% |
| Jun 30, 2023 | -299.15% |
| Mar 31, 2023 | 97.43% |
| Dec 31, 2022 | 529,957.65% |
| Sep 30, 2022 | -8,397.71% |
| Jun 30, 2022 | -1,681.75% |
| Mar 31, 2022 | -2,137.02% |
| Dec 31, 2021 | 100.23% |
| Sep 30, 2021 | 99.63% |